This question has gained attention as GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) become increasingly prescribed for type 2 diabetes and weight management
The antiallodynic effect was entirely blocked by the microglial inhibitor minocycline, -endorphin antiserum, or the opioid receptor antagonist naloxone [24]
Moberly SP, Mather KJ, Berwick ZC, Owen MK, Goodwill AG, Casalini ED, Hutchins GD, Green MA, Ng Y, Considine RV, Perry KM, Chisholm RL, Tune JD: Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus
we prioritize authentic, FDA-approved metabolic therapies The FDA has warned about dosing errors and adverse events involving compounded injectable semaglutide products
Multicenter database analyses have reported reductions of 1230% in C-reactive protein (CRP) levels among GLP-1RA users across a range of inflammatory disease indications [364]